The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients
暂无分享,去创建一个
D. Abramowicz | A. Limaye | A. Jardine | A. Humar | A. Humar | F. Vincenti | Y. Lebranchu | I. Hauser | E. Blumberg | P. Peeters | J. Punch | J. Ives | A. Voulgari